7EY Stock Chart & Stats
€0.38
€0.00(0.00%)
At close: 4:00 PM EDT
€0.38
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.38 - €0.46
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€9.38M
Enterprise Value-€258.21K
Total Cash (Recent Filing)€16.84M
Total Debt (Recent Filing)€333.02K
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 06, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.50
Shares Outstanding4,424,387
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.50
Price to Sales (P/S)0.00
P/FCF Ratio-0.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.68Price Target Upside2710.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.49
Revenue Forecast (FY)€1.34M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt reduces solvency and refinancing pressure, preserving financial flexibility while Kiora advances its pipeline. The limited interest burden also leaves more of the equity base available to support clinical development and strategic priorities over the coming quarters.
South Korea Licensing PartnershipThe CKD agreement provides external validation and a commercial pathway for KIO-301 in South Korea while adding upfront, milestone and royalty potential. Partnership coverage across major markets may also let Kiora focus internal resources on other pipeline programs.
Experienced Clinical LeadershipAdding an executive with extensive ophthalmology trial and regulatory experience can improve clinical execution, registration planning and coordination across global studies. Stronger development leadership is particularly valuable as Kiora advances retinal programs toward potentially pivotal milestones.
Bears Say
No Current Operating RevenueZero trailing revenue means Kiora currently lacks an established product-sales engine to fund operations. Combined with recurring losses, this leaves performance dependent on clinical progress, partnerships or future financing rather than a durable commercial revenue base.
Sustained Cash BurnPersistent negative operating and free cash flow indicates that ongoing development consumes cash rather than generating it. Unless programs produce partnership proceeds or eventual commercial revenue, continued investment will require careful liquidity management and may increase financing dependence.
High Earnings VolatilityThe sharp reversal from 2024 profitability to zero TTM revenue and recurring losses demonstrates limited earnings consistency. Such volatility makes operating results less predictable and complicates planning, resource allocation and assessment of sustainable financial performance.
Kiora Pharmaceuticals News
7EY FAQ
What was Kiora Pharmaceuticals’s price range in the past 12 months?
Kiora Pharmaceuticals lowest stock price was €0.38 and its highest was €0.46 in the past 12 months.
What is Kiora Pharmaceuticals’s market cap?
Kiora Pharmaceuticals’s market cap is €9.38M.
When is Kiora Pharmaceuticals’s upcoming earnings report date?
Kiora Pharmaceuticals’s upcoming earnings report date is Nov 06, 2026 which is in 16 days.
How were Kiora Pharmaceuticals’s earnings last quarter?
Kiora Pharmaceuticals released its earnings results on Aug 07, 2026. The company reported -€0.303 earnings per share for the quarter, beating the consensus estimate of -€0.419 by €0.116.
Is Kiora Pharmaceuticals overvalued?
According to Wall Street analysts Kiora Pharmaceuticals’s price is currently Undervalued.
Does Kiora Pharmaceuticals pay dividends?
Kiora Pharmaceuticals does not currently pay dividends.
What is Kiora Pharmaceuticals’s EPS estimate?
Kiora Pharmaceuticals’s EPS estimate is -0.34.
How many shares outstanding does Kiora Pharmaceuticals have?
Kiora Pharmaceuticals has 4,424,387 shares outstanding.
What happened to Kiora Pharmaceuticals’s price movement after its last earnings report?
Kiora Pharmaceuticals reported an EPS of -€0.303 in its last earnings report, beating expectations of -€0.419. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Kiora Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:7EY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
7EY Stock 12 Month Forecast
Average Price Target
€10.68
▲(2710.22% Upside)